Study of SCTT11 for thyroid eye disease
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests an investigational drug called SCTT11 in healthy people and in people with thyroid eye disease. The goal is to see if it is safe and if it can help reduce symptoms like bulging eyes and discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old (if you have thyroid eye disease).
- You have moderate to severe thyroid eye disease that affects your daily life but is not threatening your sight.
- Your thyroid function is normal or only mildly overactive or underactive.
- You have not had surgery or major trauma in the past month.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 180 days after.
- You have not participated in another clinical trial within the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This trial tests a new medicine called MHB018A for people with active thyroid eye disease (TED), a condition that causes the eyes to bulge and become inflamed. The study aims to see if the drug can reduce symptoms and improve eye appearance compared to a placebo.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Hear when a new TED trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.